Certican derives Successful Result

.

Certican derives Successful Result

Surely, it was a good news for Novartis that it has been able to have positive result of its phase III clinical study of immune system drug known as Certican. The news was worth getting happy, as it has been found that the Swiss pharmaceutical company was trying to get everything right for last two years.

In addition, it has been said that the project is considered to be the biggest project that has been taken out by the company with regard to liver transplant. It has been found that the drug is quite effective in improving renal function among patients.

The data about the same was revealed at the meeting of American Association for the Study of Liver Diseases (AASLD), which is in its 63rd year. The drug, which has already received approval from European health authorities, is likely to get approval from the US health regulators Food and Drug Administration by the end of 2012.

"These results showed that treatment with Certican with reduced tacrolimus led to a clinically relevant retention of renal function compared to standard tacrolimus, with no compromise in rejection", said John Fung, who is positioned as director at Transplantation Center. It is expected that the drug is able to provide benefit to adults suffering from liver problem.


Latest News

Abbott Laboratories Acquiring Medical Technology and Service Company St. Jude fo
Amazon Beats Expectations with Strong First Quarter Earnings Report
Michael Pearson, Valeant’s Outgoing CEO Admits Dramatic Increases of Certain Dru
Facebook Inc Posted a Better than Expected Revenue with Boost in Mobile Advertis
Organic Consumers Association Files Lawsuit against Honest Company over its Prem
SpaceX Could Land Its Dragon Spacecraft on Mars as Soon as 2018
Man fleeing robbery, jumps White House fence
Donald Trump and Hillary Clinton win big on recent big Tuesday
Twitter’s User Number Remain Almost Stagnant in the First Quarter
Japanese Carmaker Mitsubishi Admits of Misleading Fuel-Economy Testing for Some
iPhone Sales Decline for the First time
Reportedly DreamWorks Animation has a Buyer Offering More Than $3 Billion